The case for & against
Bull & Bear analysis
Bullish
ADC Therapeutics (NYSE: ADCT) is a clinical-stage biotechnology company that specializes in developing targeted antibody-drug conjugates (ADCs) for treating hematologic malignancies, particularly focusing on diffuse large B-cell lymphoma (DLBCL). The company is positioned within the oncology market, with its flagship product, Zynlanta, aimed at addressing significant clinical needs through innovative therapies. As ADC navigates the complexities of the oncology landscape, it seeks to expand its market share and capitalize on growth opportunities tied to upcoming clinical data releases and regulatory approvals.
Bull says
- ↑Q1 net product revenue grew 15% YoY to $20M
- ↑Cash position of $231M provides runway into 2028
- ↑Operating expenses cut 13% YoY boosts efficiency
- ↑Zynlanta could hit $600M–$1B peak U.S. sales
- ↑High institutional ownership signals positive sentiment
- ↑Manageable leverage and strong growth factors support resilience
Bear says
- ↓Q1 net loss stood at $33M, straining finances
- ↓Weak profitability and negative earnings yield factors persist
- ↓LOTUS-5 trial delays or failures threaten approvals
- ↓Analysts are cutting forecasts on dimming outlook
- ↓Emerging bispecific therapies heighten competitive pressure
- ↓Dependence on trial success elevates equity volatility risk
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-09-2026neutral
Transcript signals
Bull points
- So we are on track to basically share the data this quarter.
- we plan to share all the relevant information on the primary endpoints. Of course, it can be the PFS, hazard ratio, any information that we have on key secondary endpoints, as well as top line safety data.
- First quarter net product revenues were $20.0 million as compared to the prior year's first quarter net product revenues of $17.4 million. The increase was driven primarily by normal quarter-to-quarter variability in customer ordering with underlying demand broadly stable.
Bear points
- the cost of goods are going to increase because of this fixed cost that now is getting allocated.
- We expect this year to be largely in line with what the previous years are and only see a revenue trajectory increase next year.
- On a GAAP basis, we reported a net loss of $33 million for the first quarter of 2026, or 21 cents per basic and diluted share, as compared to a net loss of $38.6 million, or 36 cents per basic and diluted share, for the same period in 2025.
Read full transcript analysis ›